M&A Deal Summary

Assertio Acquires Spectrum Pharmaceuticals

On April 25, 2023, Assertio acquired life science company Spectrum Pharmaceuticals for 248M USD

Acquisition Highlights
  • This is Assertio’s 3rd transaction in the Life Science sector.
  • This is Assertio’s largest (disclosed) transaction.
  • This is Assertio’s 4th transaction in the United States.
  • This is Assertio’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2023-04-25
Target Spectrum Pharmaceuticals
Sector Life Science
Buyer(s) Assertio
Deal Type Add-on Acquisition
Deal Value 248M USD
Advisor(s) Guggenheim Securities (Financial)
Gibson, Dunn & Crutcher (Legal)

Target

Spectrum Pharmaceuticals

Boston, Massachusetts, United States
website
Spectrum Pharmaceuticals is a biotechnology company focused on acquiring, developing and commercializing drug products with a primary focus in oncology and hematology. Spectrum Pharmaceuticals was founded in 1987 and is based in Boston, Massachusetts.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Assertio

Lake Forest, Illinois, United States

website

Category Company
Founded 1995
Sector Life Science
Employees30
Revenue 156M USD (2022)
DESCRIPTION

Assertio is a pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. Assertio was founded in 1995 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 4 of 4
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 4 of 4
Year (2023) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-15 Otrexup

New Jersey, United States

Otrexup is a drug-device combination single dose once weekly auto-injector containing a prescription medicine, methotrexate, which is indicated for certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well. It is also used to control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.

Buy $44M
Mergr

Product

Company

Legal